Anthropic is reportedly acquiring AI biotech startup Coefficient Bio in a $400 million stock deal, adding a small specialist team to strengthen its capabilities in AI-driven drug discovery. The New York-based company was founded in 2025 and has only six employees, according to the source material.
The deal was first reported by The Information. Even by startup acquisition standards, the contrast stands out: a nine-figure price tag for a team of six. That has put attention on the founders and on Coefficient Bio’s focus, which TechCrunch described as using AI to improve the efficiency of drug discovery and biological research.
A tiny team with biotech leadership experience
PitchBook data cited in the source says Coefficient Bio’s CEO and co-founder, Aris Theologis, previously served as chief business officer at Evozyne and vice president at Paragon Biosciences. During his time at Evozyne, he built and expanded an AI partnership with Nvidia.
The startup’s CTO and co-founder, Nathan Frey, was chief scientist at Biogen until last September. Co-founder Joyce Hong had also spent nearly five years at Roivant Sciences. Anthropic is not buying scale here. It is buying a narrow team built around biotech and AI research expertise.
Anthropic has been building out healthcare products
The acquisition fits a broader push into life sciences. Over the past several months, Anthropic has rolled out Claude for Life Sciences, launched in October last year, and Claude for Healthcare, released in January this year.
Eric Kauderer-Abrams, Anthropic’s head of biology and life sciences, said in January that the company wants its models to support the full chain from early discovery to translational medicine and commercialization, while connecting with the tools scientists already use. Bringing in Coefficient Bio looks consistent with that strategy.
A direct answer to OpenAI’s healthcare push
The move is also being framed as a direct response to OpenAI. The source notes that OpenAI has already launched ChatGPT Health, which allows users to upload medical records, and OpenAI for Healthcare, a toolkit built for healthcare companies.
That puts both companies on the same track: applying frontier AI systems to healthcare and life sciences. Anthropic’s choice, though, is to acquire a specialist biotech startup rather than rely only on general-purpose product expansion.
Acquisition moves ahead despite federal pressure
The purchase comes while Anthropic is facing political headwinds in Washington. According to the source material, the U.S. Department of Health and Human Services ordered employees in March to stop using Claude after President Donald Trump sought to place Anthropic on a federal blacklist.
The report says the restriction could also affect processes tied to the FDA. Last summer, the FDA had introduced Elsa, an AI tool built on Claude to help accelerate drug product reviews. Even with that backdrop, Anthropic is still moving ahead with a $400 million acquisition tied to life sciences.